메뉴 건너뛰기




Volumn 128, Issue 3, 2011, Pages 599-606

"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?

Author keywords

Aromatase inhibitor; Breast cancer; Drug resistance; Everolimus; mTOR pathway; Temsirolimus

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; EVEROLIMUS; FULVESTRANT; INITIATION FACTOR 4E BINDING PROTEIN 1; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 3; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN; RIDAFOROLIMUS; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG;

EID: 79960835593     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0986-9     Document Type: Review
Times cited : (52)

References (29)
  • 1
    • 1442283866 scopus 로고    scopus 로고
    • Clinical Pharmacokinetics of Everolimus
    • DOI 10.2165/00003088-200443020-00002
    • GI Kirchner I Meier-Wiedenbach MP Manns 2004 Clinical pharmacokinetics of everolimus Clin Pharmacokinet 43 83 95 14748618 10.2165/00003088-200443020- 00002 1:CAS:528:DC%2BD2cXisFGkurY%3D (Pubitemid 38283132)
    • (2004) Clinical Pharmacokinetics , vol.43 , Issue.2 , pp. 83-95
    • Kirchner, G.I.1    Meier-Wiedenbach, I.2    Manns, M.P.3
  • 2
    • 35348917266 scopus 로고    scopus 로고
    • Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
    • DOI 10.1158/1078-0432.CCR-06-2837
    • CH Lu SL Wyszomierski LM Tseng MH Sun KH Lan CL Neal GB Mills GN Hortobagyi FJ Esteva D Yu 2007 Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency Clin Cancer Res 13 5883 5888 17908983 10.1158/1078-0432.CCR-06-2837 1:CAS:528:DC%2BD2sXhtFSntLvJ (Pubitemid 47583915)
    • (2007) Clinical Cancer Research , vol.13 , Issue.19 , pp. 5883-5888
    • Lu, C.-H.1    Wyszomierski, S.L.2    Tseng, L.-M.3    Sun, M.-H.4    Lan, K.-H.5    Neal, C.L.6    Mills, G.B.7    Hortobagyi, G.N.8    Esteva, F.J.9    Yu, D.10
  • 3
    • 25844507104 scopus 로고    scopus 로고
    • Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells
    • DOI 10.1002/ijc.21222
    • W Yue J Wang Y Li P Fan RJ Santen 2005 Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells Int J Cancer 117 746 754 15957161 10.1002/ijc.21222 1:CAS:528:DC%2BD2MXht1ShsbbN (Pubitemid 41598825)
    • (2005) International Journal of Cancer , vol.117 , Issue.5 , pp. 746-754
    • Yue, W.1    Wang, J.2    Li, Y.3    Fan, P.4    Santen, R.J.5
  • 4
    • 0036488531 scopus 로고    scopus 로고
    • Endocrine-responsive breast cancer and strategies for combating resistance
    • S Ali RC Coombes 2002 Endocrine-responsive breast cancer and strategies for combating resistance Nat Rev Cancer 2 101 112 10.1038/nrc721 12635173 10.1038/nrc721 (Pubitemid 37328797)
    • (2002) Nature Reviews Cancer , vol.2 , Issue.2 , pp. 101-112
    • Ali, S.1    Coombes, R.C.2
  • 5
    • 34548462552 scopus 로고    scopus 로고
    • Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells
    • DOI 10.1016/j.jsbmb.2007.05.008, PII S0960076007001306, Proceedings of the VIII International Aromatase Conference 'Aromastase 2006' (Baltimore, Maryland USA, 18-20 September, 2006)
    • W Yue P Fan J Wang Y Li RJ Santen 2007 Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells J Steroid Biochem Mol Biol 106 102 110 S0960-0760(07)00130-6 17616457 10.1016/j.jsbmb.2007.05.008 1:CAS:528:DC%2BD2sXhtVWitb3K (Pubitemid 47362658)
    • (2007) Journal of Steroid Biochemistry and Molecular Biology , vol.106 , Issue.1-5 , pp. 102-110
    • Yue, W.1    Fan, P.2    Wang, J.3    Li, Y.4    Santen, R.J.5
  • 6
    • 42049121934 scopus 로고    scopus 로고
    • Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
    • DOI 10.1210/er.2006-0045
    • G Arpino L Wiechmann CK Osborne R Schiff 2008 Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocr Rev 29 217 233 er.2006-0045 18216219 10.1210/er.2006-0045 1:CAS:528: DC%2BD1cXltlOhsrk%3D (Pubitemid 351519691)
    • (2008) Endocrine Reviews , vol.29 , Issue.2 , pp. 217-233
    • Arpino, G.1    Wiechmann, L.2    Osborne, C.K.3    Schiff, R.4
  • 7
    • 69249137029 scopus 로고    scopus 로고
    • Biological determinants of endocrine resistance in breast cancer
    • nrc2713 19701242 10.1038/nrc2713 1:CAS:528:DC%2BD1MXhtVegtrzL
    • EA Musgrove RL Sutherland 2009 Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 631 643 nrc2713 19701242 10.1038/nrc2713 1:CAS:528:DC%2BD1MXhtVegtrzL
    • (2009) Nat Rev Cancer , vol.9 , pp. 631-643
    • Musgrove, E.A.1    Sutherland, R.L.2
  • 8
    • 4544388665 scopus 로고    scopus 로고
    • The mTOR pathway in estrogen response: A potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas (abstract)
    • J Rudloff S Zumstein-Mecker DB Evans T O'Reilly HA Lane 2004 The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas (abstract) Proc Am Assoc Cancer Res 45 A5619
    • (2004) Proc Am Assoc Cancer Res , vol.45 , pp. 5619
    • Rudloff, J.1    Zumstein-Mecker, S.2    Evans, D.B.3    O'Reilly, T.4    Lane, H.A.5
  • 9
    • 22344446415 scopus 로고    scopus 로고
    • Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer
    • DOI 10.1158/1078-0432.CCR-04-2402
    • A Boulay J Rudloff J Ye S Zumstein-Mecker T O'Reilly DB Evans S Chen HA Lane 2005 Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 11 5319 5328 16033851 10.1158/1078-0432.CCR-04-2402 1:CAS:528:DC%2BD2MXmt12qu70%3D (Pubitemid 41003721)
    • (2005) Clinical Cancer Research , vol.11 , Issue.14 , pp. 5319-5328
    • Boulay, A.1    Rudloff, J.2    Ye, J.3    Zumstein-Mecker, S.4    O'Reilly, T.5    Evans, D.B.6    Chen, S.7    Lane, H.A.8
  • 10
    • 33745903146 scopus 로고    scopus 로고
    • Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
    • DOI 10.1016/j.ygyno.2005.12.019, PII S0090825805011212
    • O Treeck B Wackwitz U Haus O Ortmann 2006 Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells Gynecol Oncol 102 292 299 16443261 10.1016/j.ygyno.2005.12. 019 1:CAS:528:DC%2BD28XntVSlt70%3D (Pubitemid 44041641)
    • (2006) Gynecologic Oncology , vol.102 , Issue.2 , pp. 292-299
    • Treeck, O.1    Wackwitz, B.2    Haus, U.3    Ortmann, O.4
  • 12
    • 34548187212 scopus 로고    scopus 로고
    • Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
    • DOI 10.1093/annonc/mdm170
    • M Beeram QT Tan RR Tekmal D Russell A Middleton LA De Graffenried 2007 Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling Ann Oncol 18 1323 1328 17693645 10.1093/annonc/mdm170 1:STN:280:DC%2BD2srptlyhtQ%3D%3D (Pubitemid 47305004)
    • (2007) Annals of Oncology , vol.18 , Issue.8 , pp. 1323-1328
    • Beeram, M.1    Tan, Q.-T.N.2    Tekmal, R.R.3    Russell, D.4    Middleton, A.5    DeGraffenried, L.A.6
  • 13
    • 65249190250 scopus 로고    scopus 로고
    • S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation
    • M807532200 19112174 10.1074/jbc.M807532200 1:CAS:528:DC%2BD1MXisVSku7s%3D
    • RL Yamnik A Digilova DC Davis ZN Brodt CJ Murphy MK Holz 2009 S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation J Biol Chem 284 6361 6369 M807532200 19112174 10.1074/jbc. M807532200 1:CAS:528:DC%2BD1MXisVSku7s%3D
    • (2009) J Biol Chem , vol.284 , pp. 6361-6369
    • Yamnik, R.L.1    Digilova, A.2    Davis, D.C.3    Brodt, Z.N.4    Murphy, C.J.5    Holz, M.K.6
  • 17
    • 33751284806 scopus 로고    scopus 로고
    • Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
    • DOI 10.1158/0008-5472.CAN-06-1500
    • M Zakikhani R Dowling IG Fantus N Sonenberg M Pollak 2006 Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res 66 10269 10273 17062558 10.1158/0008-5472.CAN-06-1500 1:CAS:528:DC%2BD28XhtFGjsrvK (Pubitemid 44799743)
    • (2006) Cancer Research , vol.66 , Issue.21 , pp. 10269-10273
    • Zakikhani, M.1    Dowling, R.2    Fantus, I.G.3    Sonenberg, N.4    Pollak, M.5
  • 18
    • 0032499440 scopus 로고    scopus 로고
    • Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
    • DOI 10.1016/S0140-6736(97)10384-1
    • SE Hankinson WC Willett GA Colditz DJ Hunter DS Michaud B Deroo B Rosner FE Speizer M Pollak 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 351 1393 1396 9593409 10.1016/S0140-6736(97)10384-1 1:STN:280:DyaK1c3lsVansw%3D%3D (Pubitemid 28209997)
    • (1998) Lancet , vol.351 , Issue.9113 , pp. 1393-1396
    • Hankinson, S.E.1    Willett, W.C.2    Colditz, G.A.3    Hunter, D.J.4    Michaud, D.S.5    Deroo, B.6    Rosner, B.7    Speizer, F.E.8    Pollak, M.9
  • 20
    • 56949094800 scopus 로고    scopus 로고
    • Targeted therapies in breast cancer: Where are we now?
    • S0959-8049(08)00712-0 19013786 10.1016/j.ejca.2008.09.026 1:CAS:528:DC%2BD1cXhsVKltr%2FK
    • S Di Cosimo J Baselga 2008 Targeted therapies in breast cancer: where are we now? Eur J Cancer 44 2781 2790 S0959-8049(08)00712-0 19013786 10.1016/j.ejca.2008.09.026 1:CAS:528:DC%2BD1cXhsVKltr%2FK
    • (2008) Eur J Cancer , vol.44 , pp. 2781-2790
    • Di Cosimo, S.1    Baselga, J.2
  • 21
    • 26944498619 scopus 로고    scopus 로고
    • Antiestrogen-resistant human breast cancer cells require activated Protein Kinase B/Akt for growth
    • DOI 10.1677/erc.1.00946
    • T Frogne JS Jepsen SS Larsen CK Fog BL Brockdorff AE Lykkesfeldt 2005 Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth Endocr Relat Cancer 12 599 614 16172194 10.1677/erc.1.00946 1:CAS:528:DC%2BD2MXht1Sjsr3P (Pubitemid 41482995)
    • (2005) Endocrine-Related Cancer , vol.12 , Issue.3 , pp. 599-614
    • Frogne, T.1    Jepsen, J.S.2    Larsen, S.S.3    Fog, C.K.4    Brockdorff, B.L.5    Lykkesfeldt, A.E.6
  • 24
    • 0035971181 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance
    • 11139588 10.1074/jbc.M010840200 1:CAS:528:DC%2BD3MXis1Olu7k%3D
    • RA Campbell P Bhat-Nakshatri NM Patel D Constantinidou S Ali H Nakshatri 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J Biol Chem 276 9817 9824 11139588 10.1074/jbc.M010840200 1:CAS:528:DC%2BD3MXis1Olu7k%3D
    • (2001) J Biol Chem , vol.276 , pp. 9817-9824
    • Campbell, R.A.1    Bhat-Nakshatri, P.2    Patel, N.M.3    Constantinidou, D.4    Ali, S.5    Nakshatri, H.6
  • 25
    • 0036633164 scopus 로고    scopus 로고
    • Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells
    • 12479367 1:CAS:528:DC%2BD38XlsFSmtLk%3D
    • AS Clark K West S Streicher PA Dennis 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells Mol Cancer Ther 1 707 717 12479367 1:CAS:528: DC%2BD38XlsFSmtLk%3D
    • (2002) Mol Cancer Ther , vol.1 , pp. 707-717
    • Clark, A.S.1    West, K.2    Streicher, S.3    Dennis, P.A.4
  • 26
    • 33745241078 scopus 로고    scopus 로고
    • Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: A mechanism of tamoxifen resistance
    • DOI 10.1158/0008-5472.CAN-05-3243
    • Y Cui I Parra M Zhang SG Hilsenbeck A Tsimelzon T Furukawa A Horii ZY Zhang RI Nicholson SA Fuqua 2006 Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance Cancer Res 66 5950 5959 16740736 10.1158/0008-5472.CAN-05-3243 1:CAS:528:DC%2BD28XltFyju74%3D (Pubitemid 43927151)
    • (2006) Cancer Research , vol.66 , Issue.11 , pp. 5950-5959
    • Cui, Y.1    Parra, I.2    Zhang, M.3    Hilsenbeck, S.G.4    Tsimelzon, A.5    Furukawa, T.6    Horii, A.7    Zhang, Z.-Y.8    Nicholson, R.I.9    Fuqua, S.A.W.10
  • 27
    • 38149081373 scopus 로고    scopus 로고
    • Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells
    • 17942395 10.1074/jbc.M706287200 1:CAS:528:DC%2BD1cXhsFejtg%3D%3D
    • N Eckstein K Servan L Girard D Cai G von Jonquieres U Jaehde MU Kassack AF Gazdar JD Minna HD Royer 2008 Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells J Biol Chem 283 739 750 17942395 10.1074/jbc. M706287200 1:CAS:528:DC%2BD1cXhsFejtg%3D%3D
    • (2008) J Biol Chem , vol.283 , pp. 739-750
    • Eckstein, N.1    Servan, K.2    Girard, L.3    Cai, D.4    Von Jonquieres, G.5    Jaehde, U.6    Kassack, M.U.7    Gazdar, A.F.8    Minna, J.D.9    Royer, H.D.10
  • 28
    • 21744453318 scopus 로고    scopus 로고
    • ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
    • DOI 10.1038/sj.onc.1208626
    • S Svensson K Jirstrom L Ryden G Roos S Emdin MC Ostrowski G Landberg 2005 ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis Oncogene 24 4370 4379 15806151 10.1038/sj.onc. 1208626 1:CAS:528:DC%2BD2MXlsVWmt74%3D (Pubitemid 40961760)
    • (2005) Oncogene , vol.24 , Issue.27 , pp. 4370-4379
    • Svensson, S.1    Jirstrom, K.2    Ryden, L.3    Roos, G.4    Emdin, S.5    Ostrowski, M.C.6    Landberg, G.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.